Kinetic Differences and Synergistic Antiviral Effects Between Type I and Type III Interferon Signaling Indicate Pathway Independence.
The spread of acute respiratory viral infections is controlled by type I and III interferon (IFN) signaling. While the mechanisms of type I IFN signaling have been studied in detail, features that distinguish type III IFN signaling remain poorly understood. Type III IFNs play an essential role in limiting infections of intestinal and respiratory epithelial surfaces; however, type III IFNs have been shown to activate similar genes to type I IFNs, raising the question of how these IFNs differ and their signals interact. We measured the kinetics of type I and III IFN activation, functional stability, and downstream antiviral responses on A549 human lung epithelial cells. Similar kinetics were found for transcriptional upregulation and secretion of type I and III IFNs in response to infection by an RNA virus, peaking at 12 h postinfection, and both protein types had similar stabilities with functional half-lives extending beyond 2 days. Both IFNs activated potent cellular antiviral responses; however, responses to type III IFNs were delayed by 2-6 h relative to type I IFN responses. Combined treatments with type I and III IFNs produced enhanced antiviral effects, and quantitative analysis of these data with a Bliss interaction model provides evidence for independence of type I and III IFN downstream signaling pathways. This novel synergistic interaction has therapeutic implications for treatment of respiratory virus infections.
1 Department of Chemical and Biological Engineering, University of Wisconsin-Madison , Madison, Wisconsin.|2 Systems Biology Theme, Wisconsin Institute for Discovery , Madison, Wisconsin.
Emily A
EA
Voigt
1 Department of Chemical and Biological Engineering, University of Wisconsin-Madison , Madison, Wisconsin.|2 Systems Biology Theme, Wisconsin Institute for Discovery , Madison, Wisconsin.
John
J
Yin
D000998:Antiviral Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D004847:Epithelial Cells / Q000187:drug effects; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007700:Kinetics; D012328:RNA Viruses / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects*; D014158:Transcription, Genetic / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects; D014777:Virus Diseases / Q000188:drug therapy*
D000998:Antiviral Agents; D007370:Interferon Type I